Page last updated: 2024-11-05

ici 204,219 and Neoplasms

ici 204,219 has been researched along with Neoplasms in 2 studies

zafirlukast: a leukotriene D4 receptor antagonist

Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.

Research Excerpts

ExcerptRelevanceReference
"Montelukast was the most potent inhibitor (p<0."1.35Montelukast is a potent and durable inhibitor of multidrug resistance protein 2-mediated efflux of taxol and saquinavir. ( Chakravarty, G; Honer Zu Bentrup, K; Mondal, D; Roy, U, 2009)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Roy, U1
Chakravarty, G1
Honer Zu Bentrup, K1
Mondal, D1
Sun, YL1
Kathawala, RJ1
Singh, S1
Zheng, K1
Talele, TT1
Jiang, WQ1
Chen, ZS1

Other Studies

2 other studies available for ici 204,219 and Neoplasms

ArticleYear
Montelukast is a potent and durable inhibitor of multidrug resistance protein 2-mediated efflux of taxol and saquinavir.
    Biological & pharmaceutical bulletin, 2009, Volume: 32, Issue:12

    Topics: Acetates; Animals; Anti-Asthmatic Agents; Antineoplastic Agents, Phytogenic; Biological Transport; C

2009
Zafirlukast antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.
    Anti-cancer drugs, 2012, Volume: 23, Issue:8

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette

2012